PRAGUE MEDICAL REPORT, Vol 124 No 1 (2023), 5–15
Janus Kinase Inhibitors in the Treatment of Alopecia Areata
Athanasios J. Stefanis
zveřejněno: 10. 02. 2023
Alopecia areata is a disease of autoimmune origin which causes non scarring hair loss. The extent of alopecia varies from a small patch to complete scalp and body hair loss, which can have huge psychosocial impact for those affected. Treatment modalities which have been used so far included nonspecific immunosuppressive medications, such as corticosteroids, cyclosporine, and methotrexate, or topical immunomodulators, such as diphencyprone, dithranol, and squaric acid dibutylester. The recognition of the importance of Janus kinase pathway in alopecia areata pathogenesis enabled more specific approaches in treatment. Positive outcomes of Janus kinase inhibitors in several trials granted approval for baricitinib which became the first on-label treatment for alopecia areata. The aim of this review is to summarize the role, efficacy and safety of several Janus kinase inhibitors in alopecia areata.
klíčová slova: Alopecia areata; Baricitinib; Olumiant; JAK/STAT; Janus kinase inhibitors; Alopecia areata treatment
Janus Kinase Inhibitors in the Treatment of Alopecia Areata is licensed under a Creative Commons Attribution 4.0 International License.
167 x 240 mm
vychází: 4 x ročně
cena tištěného čísla: 450 Kč